Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 255-266 , March 2007

Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective

  • Juliana C.N. Chan

      Affiliations

    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hongkong
    • Corresponding Author InformationCorresponding author. Tel.: +852 2632 3138; fax: +852 2632 3108.
    • ,
  • Chaicharn Deerochanawong

      Affiliations

    • Diabetes and Endocrinology Unit, Rajavithi Hospital, Bangkok, Thailand
    • ,
  • A. Samad Shera

      Affiliations

    • Diabetic Association of Pakistan, Karachi, Pakistan
    • ,
  • Kun-Ho Yoon

      Affiliations

    • Department of Endocrinology and Metabolism, Catholic University of Korea, Seoul, Korea
    • ,
  • John M.F. Adam

      Affiliations

    • Division of Endocrinology and Metabolism, Faculty of Medicine, Hsanuddin University, Makassar, Indonesia
    • ,
  • Ta Van Binh

      Affiliations

    • National Institute of Endocrinology, Hanoi, Vietnam
    • ,
  • Siew-Pheng Chan

      Affiliations

    • University Malaya Medical Centre, Kuala Lumpur, Malaysia
    • ,
  • Richard Elwyn Fernando

      Affiliations

    • St. Luke's Medical Center, Pasay City General Hospital, Manila, Philippines
    • ,
  • Lee Chung Horn

      Affiliations

    • Diabetes and Endocrinology, Gleneagles Hospital, Singapore
    • ,
  • Nguyen Thy Khue

      Affiliations

    • Department of Endocrinology and Diabetes, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
    • ,
  • Augusto D. Litonjua

      Affiliations

    • Makati Medical Center, Manila, Philippines
    • ,
  • Sidartawan Soegondo

      Affiliations

    • Metabolic & Endocrine Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
    • ,
  • Paul Zimmet

      Affiliations

    • International Diabetes Institute, Victoria, Australia

Received 23 January 2006 ,Accepted 22 June 2006.

References 

  1. Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005;48:17–26
  2. Hong CY, Chia KS, Hughes K, Ling SL. Ethnic differences among Chinese, Malay and Indian patients with type 2 diabetes mellitus in Singapore. Singapore Med. J. 2004;45:154–160
  3. Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. Diabetes Res. Clin. Pract. 1989;7:33–40
  4. Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes. Available at www.idf.org.
  5. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 diabetes: practical targets and treatments Fourth edition http://www.diabetes.com.au/pdf/Diabetes_TreatmentTargets_FINAL.pdf, last accessed November 2005.
  6. International Diabetes Federation e-atlas of diabetes, available at http://www.eatlas.idf.org. (last accessed September 2005).
  7. Zimmet P. The burden of type 2 diabetes: are we doing enough?. Diabetes Metab. 2003;29:6S9–6S18
  8. Cheung BM. The cardiovascular continuum in Asian--a new paradigm for the metabolic syndrome. J. Cardiovasc. Pharmacol. 2005;46:125–129
  9. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl. 1):S4–S36
  10. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012
  11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 2000;321:405–412
  12. Consoli A, Gomis R, Halimi S, Home PD, Mehnert H, Strojek K, et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab. 2004;30:509–516
  13. Donnelly LA, Doney ASF, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabetes Med. 2006;23:128–133
  14. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes. 1999;48:2182–2188
  15. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab. 2003;29:6S88–6S94
  16. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29:6S28–6S35
  17. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem. Pharmacol. 2000;59:887–890
  18. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabetes Med. 2005;22:980–985
  19. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 1993;16:1035–1038
  20. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16:621–629
  21. Ahn YB, Son HY. Efficacy of metformin monotherapy in patients with NIDDM in Korea. In:  Shinn SH,  Shichiri M,  Kim K-W editor. New Therapeutic Approaches in Diabetes Mellitus. Recent Advances on the Pathogenesis and Management of Diabetes Mellitus. Elsevier Science (Singapore) Pte Ltd.; 1998;p. 49–54
  22. Mughal MA, Jan M, Maheri WM, Memon MY, Ali M. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control. J. Pak. Med. Assoc. 2000;50:381–386
  23. Ohmura C, Tanaka Y, Mistuhashi N, Atsum Y, Matsuoka K, Onuma T, et al. Efficacy of low-dose metformin in Japanese patients with type 2 diabetes mellitus. Curr. Ther. Res. 1996;59:889–895
  24. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27:1496–1504
  25. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 2004;256:1–14
  26. Després JP. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab. 2003;29:6S53–6S61
  27. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab. Rev. 1995;11(Suppl. 1):S57–S62
  28. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA 285 (2001) 2486–2497.
  29. Fujimoto WY, Bergstrom RW, Boyko EJ, Leonetti DL, Newell-Morris LL, Wahl PW. Susceptibility to development of central adiposity among populations. Obes. Res. 1995;3(Suppl. 2):179S–186S
  30. Grundy SM. What is the contribution of obesity to the metabolic syndrome?. Endocrinol. Metab. Clin. North Am. 2004;33:267–282
  31. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  32. Kurukulasuriya R, Banerji MA, Chaiken R, Lebovitz H. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes. Diabetes. 1999;48:A315
  33. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2001;37:1344–1350
  34. Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 2004;89:3943–3948
  35. Pavlović D, Kocić R, Kocić G, Jevtovic T, Radenkovic S, Mikic D, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes. Metab. 2000;2:251–256
  36. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 2003;29(6):S77–S87
  37. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. 2003;29(6):S71–S76
  38. Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2004;64:225–228
  39. Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47:1906–1913
  40. Schäfers RF. Do effects on blood pressure contribute to improved clinical outcomes with metformin?. Diabetes Metab. 2003;29:6S62–6S70
  41. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64–66
  42. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29:6S44–6S52
  43. Grant PJ. Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus. Thromb. Haemost. 1998;80:209–210
  44. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488
  45. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab. 2003;29:6S95–6S103
  46. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2003;88:4649–4654
  47. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine. 2003;20:215–218
  48. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J. Clin. Endocrinol. Metab. 2004;89:5043–5047
  49. Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  50. Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  51. UKPDS Group. UK Prospective Diabetes Study 6. Complications in newly-diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 1990;13:1–11
  52. Kao J, Tobis J, McClelland RL, Davis BR, Holmes DR, Currier JW. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am. J. Cardiol. 2004;93:1347–1350
  53. Sgambato S, Varricchio M, Tesauro P, Passariello N, Carbone L. L’utilisation de la metformin dans la cardiopathie ischemique. Clin. Ter. 1980;94:77–85
  54. Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003;29:6S36–6S43
  55. Sirtori CR, Franceschini G, Gianfranceschi G, Sirtori M, Montanari G, Bosisio E, et al. Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J. Cardiovasc. Pharmacol. 1984;6:914–923
  56. Montaguti U, Celin D, Ceredi C, Descovitch GC. Efficacy of the long-term administration of metformin in hyperlipidaemic patients. Res. Clin. Forums. 1979;1:95–103
  57. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–2248
  58. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, et al. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield; 2001;Available at www.nice.org.uk (last accessed by author December 2004)
  59. World Health Organization Regional Office for the Western Pacific, International Diabetes Federation (Western Pacific Region), Secretariat of the Pacific Community, The Western Pacific Declaration on Diabetes (2003).
  60. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–1062
  61. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 1997;103:491–497
  62. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2001;1:28–36
  63. Howlett H, Davidson J. New prolonged-release metformin improves gastrointestinal tolerability. Br. J. Diabetes Vasc. Dis. 2004;4:273–277
  64. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J. Pediatr. Endocrinol. Metab. 2000;13(Suppl. 6):1395–1402
  65. Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care. 1999;22:944–950
  66. Wiegand S, Maikowski U, Blankenstein O, Biebermann H, Tarnow P, Gruters A. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity—a problem that is no longer restricted to minority groups. Eur. J. Endocrinol. 2004;151:199–206
  67. McMahon SK, Haynes A, Ratnam N, Grant MT, Carne CL, Jones TW, et al. Increase in type 2 diabetes in children and adolescents in Western Australia. Med. J. Aust. 2004;180:459–461
  68. Narayan KM, Fagot-Campagna A, Imperatore G. Type 2 diabetes in children: a problem lurking for India?. Indian Pediatr. 2001;38:701–704
  69. Kitagawa T, Owada M, Urakami T, Tajima N. Epidemiology of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in Japanese children. Diabetes Res. Clin. Pract. 1994;24(Suppl.):S7–S13
  70. Cockram CS. The epidemiology of diabetes mellitus in the Asian-Pacific region. Hong Kong Med. J. 2000;6:43–52
  71. Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA. 2003;290:1345–1350
  72. Likitmaskul S, Kiattisathavee P, Chaichanwatanakul K, et al. Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity. J. Pediatr. Endocrinol. Metab. 2003;16:71–77
  73. Huen KF, Low LC, Wong GW, Tse WW, Yu AC, Lam YY, et al. Epidemiology of diabetes mellitus in children in Hong Kong: the Hong Kong childhood diabetes register. J. Pediatr. Endocrinol. Metab. 2000;13:297–302
  74. Silink M. Childhood diabetes: a global perspective. Horm. Res. 2002;57(Suppl. 1):1–5
  75. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation consensus workshop. Diabetes Care. 2004;27:1798–1811
  76. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89–94
  77. Coetzee EJ, Jackson WP. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res. Clin. Pract. 1985–86;1:281–287
  78. Glucophage® Prescribing Information, Merck KGaA.
  79. Ko GT, Chan JC, Chow CC, Yeung VT, Li YK, Cockram CS. Phenformin-induced lactic acidosis: an almost forgotten complication of treatment with biguanides. Br. J. Hosp. Med. 1995;54:469–470
  80. Yeoh KG, Lee KO, Cheah JS. Fatal lactic acidosis from imported phenformin—report of two cases. Singapore Med. J. 1996;37:482–484
  81. Lu HC, Parikh PP, Lorber DL. Phenformin-associated lactic acidosis due to imported phenformin. Diabetes Care. 1996;19:1449–1450
  82. US Food and Drug Administration press release, Sino American Health Products, Inc., Issues a National Recall of Herbal Products Due to the Presence of the Undeclared Drugs Glyburide and Phenformin. Available at http://www.fda.gov/oc/po/firmrecalls/Zhenqi.html, accessed November 2005.
  83. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care. 2005;28:539–543
  84. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2003;2:CD002967
  85. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med. 2003;163:2594–2602
  86. Chan NN, Fauvel NJ, Feher MD. Non-steroidal anti-inflammatory drugs and metformin: a cause for concern?. Lancet. 1998;352:201
  87. Price G. Metformin lactic acidosis, acute renal failure and rofecoxib. Br. J. Anaesth. 2003;91:909–910
  88. Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant?. Diabetes Care. 2003;26:2471–2472
  89. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol. 1987;23:545–551
  90. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point?. Diabetologia. 2005;48:2454–2459
  91. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 2003;254:455–463
  92. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23:1227–1231
  93. Liu KW, Dai LK, Jean W. Metformin-related vitamin B12 deficiency. Age Ageing. 2006;35:200–201
  94. Ma R, Chow C, Tong P, Chan J, Cockram C. To: A. Holsetin, M. Stumvoll (2006) Contraindications can damage your health—is metformin a case in point?. Diabetologia. 2006;48:2454–2459Diabetologia 49 (2006) 1127–8

PII: S0168-8227(06)00292-0

doi: 10.1016/j.diabres.2006.06.023

Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 255-266 , March 2007

Article Tools

* Image Usage & Resolution